← All compounds · evidence tier first, by design
| Use | E1 | E2 | E3 | E4 | E5 | E6 | E7 | E8 |
|---|---|---|---|---|---|---|---|---|
| E3 Ulcerative colitis and inflammatory bowel disease | E3 | |||||||
| E4 Interstitial cystitis (bladder pain syndrome) | E4 | |||||||
| E5 Tendon, ligament, muscle and joint injury | E5 | |||||||
| E6 Stomach and gut lining injury (ulcers, NSAID damage, 'leaky gut') | E6 |
BPC-157
GEPPPGKPADDAGLV
Free base; CAS number as given for BPC-157 (free base) in FDA's July 2026 briefing document. BPC-157 acetate is a distinct salt form. Described by its originators as a fragment of a protein from gastric juice.
Also: BPC 157, Body Protection Compound-157, Bepecin, Stable gastric pentadecapeptide BPC 157 · Codes: PL 14736, PL-10, PLD-116 · CAS 137525-51-0
A synthetic 15-amino-acid peptide first described by a research group in Zagreb in 1993. It is sold widely on the gray market and through some clinics with claims of tendon, ligament, muscle and gut "healing". FDA's July 2026 briefing document states that no product containing it is approved in any country. Almost all published efficacy data are from rodent studies, most from a single research group; human data are limited to small uncontrolled reports and one trial reported only as a conference abstract.
- US C gray market
- EU ? not verified
- UK ? not verified
- CA ? not verified
- AU ? not verified
- JP ? not verified
- CN ? not verified
01Regulatory status, by jurisdiction
| Jurisdiction | Status | Detail and primary source |
|---|---|---|
| US | Not approved | No FDA-approved product. BPC-157 was formerly in 503A Category 2 (substances raising significant safety risks); the nominations were withdrawn and it now appears on FDA's list of substances nominated but withdrawn. FDA re-evaluated BPC-157 (free base) and BPC-157 acetate on its own initiative, for ulcerative colitis only, for the Pharmacy Compounding Advisory Committee meeting of 23 July 2026. FDA's briefing document recommended against adding either form to the 503A bulks list. The committee's vote and any final FDA decision were not verified from an FDA source for this record.“After considering the information currently available, a balancing of the criteria weighs against BPC-157 (free base) and BPC-157 acetate being placed on that list”July 23-24, 2026, Meeting of the Pharmacy Compounding Advisory Committee – FDA Briefing Document for BPC-157-Related Bulk Drug Substances (BPC-157 (free base) and BPC-157 acetate) · retrieved 2026-10-10 |
| US | Not approved | FDA's page on bulk drug substances that may present significant safety risks lists BPC-157 under 'Bulk drug substances nominated but withdrawn' (substances previously in Category 2) and gives FDA's stated risks. Page content current as of 22 April 2026.“Compounded drugs containing BPC-157 may pose risk for immunogenicity for certain routes of administration and may have complexities with regard to peptide-related impurities and active pharmaceutical ingredient (API) characterization.”Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks · retrieved 2026-10-10 |
| EU UK CA AU JP CN | Not yet verified from a primary source. No status is shown rather than an unsourced one. | |
Sport (WADA): Prohibited · class S0. Named in class S0 (non-approved substances), prohibited at all times, on the 2026 Prohibited List. “This class covers many different substances including but not limited to BPC-157, 2,4-dinitrophenol (DNP), ryanodine receptor-1-calstabin complex stabilizers” WADA source
02What the human evidence shows
Ulcerative colitis and inflammatory bowel disease
An enema formulation (PL 14736) was developed by the Croatian company Pliva for inflammatory bowel disease in the early 2000s. FDA's 2026 briefing document identified a single randomised, double-blind, placebo-controlled trial in 53 people with mild-to-moderate ulcerative colitis, reported only as a 2005 conference abstract; the between-group difference in its disease-activity score was not statistically significant. FDA concluded that there is a lack of evidence to support effectiveness in ulcerative colitis. Other data are from rat models. The developers' review cited here describes the clinical programme but reports no trial results.
- [1] Review by the originating group describing the inflammatory bowel disease clinical programme and rat gastric-lesion experiments; no human efficacy results reported
- [2] Reduced visible mucosal damage and oxidative-stress markers in a rat model of ischaemic colitis
Registered-study counts: ClinicalTrials.gov intervention search “BPC-157”, fetched 2026-10-10. Registered studies include trials of other uses; the gap between registered and reported is itself a finding.
Interstitial cystitis (bladder pain syndrome)
No randomised controlled trial in humans has been published for this use.
One uncontrolled single-clinic pilot study injected compounded BPC-157 into the bladder wall of 12 women whose interstitial cystitis had not responded to pentosan polysulfate, and reported symptom resolution on a global response questionnaire. There was no control group, no blinding and no objective outcome measure, so placebo response and natural fluctuation cannot be excluded.
- [3] Uncontrolled pilot study in 12 women; self-rated symptom improvement reported, no comparator
Registered-study counts: ClinicalTrials.gov intervention search “BPC-157”, fetched 2026-10-10. Registered studies include trials of other uses; the gap between registered and reported is itself a finding.
Tendon, ligament, muscle and joint injury
No human trial of any design has been published for this use.
The musculoskeletal claims rest on rat studies of cut or detached tendons, ligaments and muscles, nearly all from one Zagreb group. The only human report is a retrospective chart review with telephone follow-up of 16 clinic patients given intra-articular injections for knee pain of mixed causes, some with a second peptide; it had no control group and no standardised outcome measure. No randomised or prospective controlled human study has been published. FDA's 2026 briefing document states that it did not identify clinical studies of BPC-157 for tendonitis. A placebo-controlled hamstring-strain trial and a rotator-cuff pilot trial are registered but have not reported.
- [4] Retrospective chart review with telephone survey of 16 clinic patients with knee pain; no control group, no validated outcome measures
- [5] Improved biomechanical, functional and histological measures after Achilles tendon transection in rats
- [6] Improved functional, biomechanical and histological measures after medial collateral ligament transection in rats
Registered-study counts: ClinicalTrials.gov intervention search “BPC-157”, fetched 2026-10-10. Registered studies include trials of other uses; the gap between registered and reported is itself a finding.
Stomach and gut lining injury (ulcers, NSAID damage, 'leaky gut')
No human trial of any design has been published for this use.
Many rat experiments report fewer stomach and intestinal lesions when BPC-157 is given alongside alcohol, anti-inflammatory drugs or other injuries. No human study of gastric ulcers, drug-induced gut injury, intestinal permeability or general digestive symptoms has been published.
- [7] Fewer gastric, liver and brain lesions after high-dose celecoxib in rats given BPC-157
Registered-study counts: ClinicalTrials.gov intervention search “BPC-157”, fetched 2026-10-10. Registered studies include trials of other uses; the gap between registered and reported is itself a finding.
Key registered trials
| NCT | Title (as registered) | Phase | Status |
|---|---|---|---|
| NCT02637284 | PCO-02 - Safety and Pharmacokinetics Trial | 1 | Unknown |
| NCT07437547 | BPC 157 for Acute Hamstring Muscle Strain Repair | 2 | Recruiting |
| NCT07803250 | Impact of BPC-157 on Recovery Following Rotator Cuff Repair Surgery | 1 | Not yet recruiting |
03Safety signals
There are no adequate human safety data. The absence of reported harm is not evidence of safety.
- Adverse event reports with injected products (FDA FAERS) [8]
FDA's 2026 briefing document summarises three FAERS reports, all with injectable BPC-157: injection-site redness and swelling, shortness of breath leading to an emergency visit, and diffuse skin and gum hyperpigmentation that recurred on rechallenge with a 'research purposes only' product that also contained TB-500. FDA states that causality cannot be established from these reports. - Clotting and liver findings in animal toxicity studies [8]
FDA reports that 28-day intramuscular toxicity studies in rats and dogs showed altered clotting times (aPTT) and liver-associated changes (raised ALT, glucose and triglycerides); longer studies and carcinogenicity studies were not available.
04What is unknown
- No published randomised controlled trial of BPC-157 for any musculoskeletal injury; registered hamstring and rotator-cuff trials have not reported
- No human pharmacokinetic data after oral, subcutaneous, nasal or transdermal use; FDA reports that plasma levels were undetectable after rectal enemas in early studies
- The full results of the 2005 ulcerative colitis trial were never published in a peer-reviewed journal
- Nearly all animal efficacy studies come from one research group, and independent replication is sparse
- No carcinogenicity studies and no repeat-dose toxicity studies longer than 28 days were available to FDA; clotting and liver findings in rats and dogs have not been followed up
- Which form (free base or acetate) and what purity is in gray-market products is unverified; FDA judged both forms not well characterised
- Regulatory status outside the US was not verified from regulator sources for this record
05Product quality
No independent purity results have been published for this compound yet. The purity programme will publish full methods and vendor-named results, passes and failures, once its protocol has had legal review.
06Citations
- Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease (PL-10, PLD-116, PL 14736, Pliva, Croatia). Full and distended stomach, and vascular response (2006). doi:10.1007/s10787-006-1531-7
- Stable gastric pentadecapeptide BPC 157 in the treatment of colitis and ischemia and reperfusion in rats: New insights (2017). doi:10.3748/wjg.v23.i48.8465
- Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study. (2024). PMID 39325560
- Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. (2021). PMID 34324435
- Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth (2003). doi:10.1016/S0736-0266(03)00110-4
- Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat (2010). doi:10.1002/jor.21107
- Celecoxib-induced gastrointestinal, liver and brain lesions in rats, counteraction by BPC 157 or L-arginine, aggravation by L-NAME (2017). doi:10.3748/wjg.v23.i29.5304
- FDA Evaluation of BPC-157-Related Bulk Drug Substances. https://www.fda.gov/media/193343/download
Every DOI is resolved against Crossref and every NCT number against ClinicalTrials.gov, title for title, before publication. Regulatory sources are cited inline above with a verbatim quote and retrieval date.
07Mechanism
The molecular target of BPC-157 has not been identified. In rodent and cell studies it has been associated with changes in nitric oxide signalling, blood vessel growth markers and growth-factor receptor expression; FDA's 2026 review describes its mechanism as poorly understood.
Mechanism is placed last on purpose: a plausible mechanism is not evidence that a compound works in people.
Reviewed by OSMF research team (AI-assisted, source-verified) on 2026-10-10. Found an error? It goes in the corrections log: report it.